Exchange: NASDAQ·Updated 07:39 PM EST
ARVN logo

ARVN Arvinas Inc

$6.34
$0.28
(4.15%)
Today
Closed $6.46
$0.12
(1.86%)
After Hours
Reported EarningsNov 3
Mkt Cap$423.03M
Vol1.11M

About ARVN

Arvinas, Inc. is a biopharmaceutical company, which engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its product candidates are ARV-110, a proteolysis targeting chimera (PROTAC) protein degrader that is in phase I clinical trial targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer, ARV-471, and ARV-766, a PROTAC protein degrader targeting the estrogen receptor protein for the treatment of patients with metastatic ER positive/HER2 negative breast cancer. The company was founded in February 2013 and is headquartered in New Haven, CT.
46

Neutral Sentiment

How do you feel about ARVN?

Massimo21
$ARVN From ASH 2026 abstract, "ARV-393, an oral PROTAC BCL6 degrader, in patients with non-Hodgkin lymphoma: Preliminary results from a phase 1 study". Preliminary PK demonstrated dose-dependent increases in ARV-393 exposure, with steady-state trough concentrations below the predicted efficacious exposure range for DLBCL and approaching the lower bound at 35 mg QD. Preliminary antitumor activity, including complete responses (CRs), was observed in evaluable pts with B-cell NHL (including FL and large B-cell lymphoma) and T-cell lymphomas treated at dose levels up to 35 mg QD, with dose escalation ongoing. Among 9 evaluable pts with nTFHL-AI, objective responses were observed in 4, including 3 CRs. Evidence of BCL6 degradation was observed in PBMCs and across B- and T-cell tumors.
3
Regulator06
$ARVN FWIW, regarding ARV-110, “…Nearly 60 percent of the participants whose tumors harbored the gene mutations T878/H875 saw their prostate-specific antigens drop by at least half.” Glta!
2
oaksapollo
$ARVN Not sure why they didn't put any of the data in the press release, but here is the full abstract.
2
ArizonaPhD
$ARVN Pain everyday, strategy has not changed, continue to accumulate and hold for years to come
1
Massimo21
$ARVN ARV-806 presentations at 38th EORTC–NCI–AACR Symposium, 18–20 November 2026 Oral 7: ARV-806, a PROTAC KRAS G12D Degrader, in Patients With KRAS G12D–Mutated Advanced Solid Tumors: Preliminary Phase 1 Results Posters 289: Preclinical Efficacy of ARV-806, a PROTAC KRAS G12D Degrader, in Combination With Chemotherapy in KRAS G12D–Mutated Pancreatic Cancer Models 290: Preclinical Efficacy of ARV-806, a PROTAC KRAS G12D Degrader, in Combination With Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibodies (mAbs) in KRAS G12D–Mutated Colorectal Cancer (CRC) Models 291: Preclinical Efficacy of ARV-806, a PROTAC KRAS G12D Degrader, in Combination With the RAS-ON Multi-Selective Inhibitor Daraxonrasib in KRAS G12D–Mutated Models
1
Regulator06
$ARVN Added! Can’t go wrong with the first company to be approved for PROTAC degrader. Glta!
1
shoc24
$ARVN reported earnings this morning before the open and beat EPS estimates with a smaller loss: -$0.82 GAAP EPS vs -$0.8762 expected, according to Stock Meadow.
1
buyandsold
$ARVN Shareholders are funding an experiment project producing some very interesting science. What would be more interesting is money in their pockets. liquidate.
1
NewGuyHere94
$ARVN the distrust the market has in here is wild, still just a gold mine of opportunity.
NewGuyHere94
$ARVN essentially a reset of where this stock was april 2025, back on the train to the next phases.
StocktwitsEarnings
$ARVN Q3 '26 Earnings Results & Recap • Reported GAAP EPS of -$0.82 down -70.83% YoY • Reported revenue of $0.5M down -98.81% YoY • Arvinas believes its cash, cash equivalents, restricted cash, and marketable securities as of September 30, 2026, are sufficient to fund planned operating expenses and capital expenditure requirements into the second half of 2028.

Advertisement|Remove ads.